Physician profile
Sandra Arias
NPI 1417787805
$2,298.20
in general payments reported to CMS, 2019-2025
13 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $631 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.80 | 2024-2025 | |
| Janssen Biotech, INC. | $484.52 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $193.38 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $189.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $174.74 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.22 | 2024-2025 | Entyvio |
| Novo Nordisk INC | $92.18 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $70.65 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $53.21 | 2025 | Zenpep |
| Lilly USA, LLC | $47.97 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $47.13 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.84 | 2025 | Xifaxan |
| Genzyme Corporation | $29.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.